Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0OW9L
|
||||
| Former ID |
DNCL001963
|
||||
| Drug Name |
MK-3134
|
||||
| Indication | Dementia [ICD9: 290-294; ICD10:F01-F07] | Phase 1 | [1] | ||
| Company |
Merck
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Histamine H3 receptor | Target Info | Agonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Reactome | Histamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Monoamine Transport | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00887601) BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006). U.S. National Institutes of Health. | ||||
| REF 2 | Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. Psychopharmacology (Berl). 2011 Dec;218(3):513-24. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.